Ginkgo Bioworks (DNA) Morgan Stanley 22nd Annual Global Healthcare Conference summary

Key accomplishments and business model evolution

• Executed a 35% reduction in force to align costs, especially in the solutions business, focusing on supporting work with customer fees rather than future royalties and milestones.

• Maintains a services-based R&D partnership model, working with major clients in agriculture, pharma, and industrial biotech, without developing its own product pipeline.

• Shifted to a more focused approach, narrowing offerings to pharma, industrial, and ag solutions, leveraging prior experience and assets.

• Retains core assets in high-throughput Foundry and Codebase, now moving away from broad IP reuse in customer projects to developing generalizable assets internally.

• Ended Q2 with $730 million in cash and no debt, providing flexibility for growth investments.

Growth strategy and new offerings

• Investing in tools and robotics, transitioning from internal use to direct sales, including proprietary modular lab automation hardware and software.

• Launched a lab data-as-a-service product, Datapoints, offering large-scale, high-quality biological datasets for AI/ML applications in drug discovery.

• Monetization of robotics includes flexible models: CapEx, leasing, and recurring SaaS revenue for software and services.

• Plans to scale the tools business by establishing marquee customers and leveraging enterprise sales capabilities.

• Aims to democratize access to its platform, enabling external scientists to use Foundry and Codebase directly.

Market positioning and industry trends

• Sees opportunity in providing high-throughput, standardized lab data to support AI-driven biotech, addressing gaps in public datasets and fine-tuning models.

• Biosecurity business is transitioning to multi-year, baseline monitoring contracts, with episodic surges during outbreaks, as seen in the $94M CDC contract.

• Remains committed to a horizontal platform model, aspiring to be the high-throughput, robotics-enabled equivalent of leading tools companies.

• Believes the horizontal approach is validated by trends in other engineering fields and the growing demand for scalable, flexible biotech infrastructure.

• Mission remains to make biology easier to engineer, focusing on enabling others rather than developing end products.